Cargando…

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

SIMPLE SUMMARY: Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dicitore, Alessandra, Gaudenzi, Germano, Carra, Silvia, Cantone, Maria Celeste, Oldani, Monica, Saronni, Davide, Borghi, Maria Orietta, Grotteschi, Jacopo, Persani, Luca, Vitale, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669991/ https://www.ncbi.nlm.nih.gov/pubmed/38001635 http://dx.doi.org/10.3390/cancers15225375

Ejemplares similares

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
por: Carra, Silvia, et al.
Publicado: (2022)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines
por: Dicitore, A., et al.
Publicado: (2021)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies
por: Vitale, Giovanni, et al.
Publicado: (2023)

Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach
por: Gentilini, Davide, et al.
Publicado: (2017)

Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
por: Pagnuzzi-Boncompagni, Marina, et al.
Publicado: (2021)

8-Chloro-Cyclic AMP and Protein Kinase A I-Selective Cyclic AMP Analogs Inhibit Cancer Cell Growth through Different Mechanisms
por: Lucchi, Simona, et al.
Publicado: (2011)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

SMYD3 promotes the epithelial–mesenchymal transition in breast cancer
por: Fenizia, Claudio, et al.
Publicado: (2019)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Crucial role of zebrafish prox1 in hypothalamic catecholaminergic neurons development
por: Pistocchi, Anna, et al.
Publicado: (2008)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

"Carcinoide" /
por: Selem Zacarias, Anuar Antonio
Publicado: (1988)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
por: Koksal, Ulkuhan I., et al.
Publicado: (2020)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Beyond the Checkpoint: Severe Axitinib-induced Liver Injury
por: Yeo, Yee Hui, et al.
Publicado: (2023)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
por: Vella, Veronica, et al.
Publicado: (2021)

Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female
por: Cogen, Jonathan D., et al.
Publicado: (2016)

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome
por: Shogbesan, Oluwaseun, et al.
Publicado: (2018)

Angpt2/Tie2 autostimulatory loop controls tumorigenesis
por: Karabid, Ninelia Minaskan, et al.
Publicado: (2022)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications
por: Vitale, Giovanni, et al.
Publicado: (2021)

The Carcinoid Syndrome
por: Strahan, Jack
Publicado: (1961)

Cannot write session to /tmp/vufind_sessions/sess_1f8jlq5mrshia15b3ck16vbuk4